Key Activities

Key achievements 2015

  • Zymenex devoted the company's Research and Development efforts to the recombinant enzyme, Lamazym, for treatment of the Lysosomal Storage Disease, alpha-Mannosidosis and the recombinant enzyme Galaczym for Krabbe disease and Agazym for Aspartylglucosaminuria. 
  • Zymenex is conducting a Phase 3 placebo controlled clinical trial in patients with alpha-Mannosidosis. The aim of the trial, which takes place at the Department of Clinical Genetics, Copenhagen University Hospital, Denmark, is to confirm the chosen weekly minimum effective dose of 1 mg/kg and to validate the clinical effect of repeated i.v dosing.
Zymenex A/S Roskildevej 12 C
3400 Hillerød, DK
Tel  +45 48250054
Fax  +45 48251054
Affiliate Sweden Agavägen 58
181 55 Lidingö, S
Tel  +46 8 7670203
Fax  +46 8 7670233

© 2004 Zymenex A/S